Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AL002

Other · developed by Alector

Phase 2 Most advanced trial (none active)

ALEC Developer

1 Registered trials

What is AL002?

AL002 is an agent given by intravenous infusion and studied in Alzheimer's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Neurology
Developer: Alector Inc. (ALEC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05744401	Phase 2	Alzheimer's Disease	Terminated	ALEC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer's Disease

More from Alector

AL003 Phase 1 GSK4527226 Phase 2 Osugacestat Phase 1

Sources

ClinicalTrials.gov NCT05744401

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALEC page.

Follow ALEC, the company behind AL002

See ALEC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALEC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z